Literature DB >> 34373096

Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.

Dara S Ross1, Fresia Pareja2.   

Abstract

Breast cancer is a heterogenous disease with various histologic subtypes, molecular profiles, behaviors, and response to therapy. After the histologic assessment and diagnosis of an invasive breast carcinoma, the use of biomarkers, multigene expression assays and mutation profiling may be used. With improved molecular assays, the identification of somatic genetic alterations in key oncogenes and tumor suppressor genes are playing an increasingly important role in many areas of breast cancer care. This review summarizes the most clinically significant somatic alterations in breast tumors and how this information is used to facilitate diagnosis, provide potential treatment options, and identify mechanisms of resistance.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Breast cancer; Estrogen receptor; HER2; Mechanisms of resistance; Mutation profiling; Resistance

Mesh:

Substances:

Year:  2021        PMID: 34373096      PMCID: PMC8363111          DOI: 10.1016/j.path.2021.05.009

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  98 in total

1.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.

Authors:  T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 2.  Salivary gland-like tumours of the breast: surgical and molecular pathology.

Authors:  M Pia-Foschini; J S Reis-Filho; V Eusebi; S R Lakhani
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

3.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 4.  Problematic breast tumors reassessed in light of novel molecular data.

Authors:  Fresia Pareja; Britta Weigelt; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

5.  ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.

Authors:  David Chu; Costanza Paoletti; Christina Gersch; Dustin A VanDenBerg; Daniel J Zabransky; Rory L Cochran; Hong Yuen Wong; Patricia Valda Toro; Justin Cidado; Sarah Croessmann; Bracha Erlanger; Karen Cravero; Kelly Kyker-Snowman; Berry Button; Heather A Parsons; W Brian Dalton; Riaz Gillani; Arielle Medford; Kimberly Aung; Nahomi Tokudome; Arul M Chinnaiyan; Anne Schott; Dan Robinson; Karen S Jacks; Josh Lauring; Paula J Hurley; Daniel F Hayes; James M Rae; Ben Ho Park
Journal:  Clin Cancer Res       Date:  2015-08-10       Impact factor: 12.531

6.  Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.

Authors:  Fresia Pareja; Michael S Toss; Felipe C Geyer; Edaise M da Silva; Mahsa Vahdatinia; Ana Paula M Sebastiao; Pier Selenica; Austin Szatrowski; Marcia Edelweiss; Hannah Y Wen; Raluca Mihai; Zsuzsanna Varga; Maria P Foschini; Brian P Rubin; Ian O Ellis; Sarat Chandarlapaty; Achim A Jungbluth; Edi Brogi; Britta Weigelt; Jorge S Reis-Filho; Emad A Rakha
Journal:  Histopathology       Date:  2020-05       Impact factor: 5.087

Review 7.  NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.

Authors:  Alessio Amatu; Andrea Sartore-Bianchi; Salvatore Siena
Journal:  ESMO Open       Date:  2016-03-18

8.  Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Authors:  Felipe C Geyer; Anqi Li; Anastasios D Papanastasiou; Alison Smith; Pier Selenica; Kathleen A Burke; Marcia Edelweiss; Huei-Chi Wen; Salvatore Piscuoglio; Anne M Schultheis; Luciano G Martelotto; Fresia Pareja; Rahul Kumar; Alissa Brandes; Dan Fan; Thais Basili; Arnaud Da Cruz Paula; John R Lozada; Pedro Blecua; Simone Muenst; Achim A Jungbluth; Maria P Foschini; Hannah Y Wen; Edi Brogi; Juan Palazzo; Brian P Rubin; Charlotte K Y Ng; Larry Norton; Zsuzsanna Varga; Ian O Ellis; Emad A Rakha; Sarat Chandarlapaty; Britta Weigelt; Jorge S Reis-Filho
Journal:  Nat Commun       Date:  2018-05-08       Impact factor: 14.919

9.  CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer.

Authors:  José Roberto F Caldeira; Erika C Prando; Francisco C Quevedo; Francisco A Moraes Neto; Cláudia A Rainho; Silvia R Rogatto
Journal:  BMC Cancer       Date:  2006-03-02       Impact factor: 4.430

10.  Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.

Authors:  M S Kim; E G Jeong; N J Yoo; S H Lee
Journal:  Br J Cancer       Date:  2008-04-08       Impact factor: 7.640

View more
  2 in total

Review 1.  Molecular Oncology of Bladder Cancer from Inception to Modern Perspective.

Authors:  Soum D Lokeshwar; Maite Lopez; Semih Sarcan; Karina Aguilar; Daley S Morera; Devin M Shaheen; Bal L Lokeshwar; Vinata B Lokeshwar
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

Review 2.  From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine.

Authors:  Sean M Hacking; Evgeny Yakirevich; Yihong Wang
Journal:  Cancers (Basel)       Date:  2022-07-17       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.